Abstract
This chapter focuses on hypertension during pregnancy, a common clinical problem and one of the main causes of maternal and perinatal morbidity and mortality. Drug treatment of hypertension during pregnancy is controversial not only because of our lack of understanding of cardiovascular physiology in normal pregnancy, but also because there is a clinical spectrum of hypertensive disorders in pregnancy making an aetiologic diagnosis difficult by clinical criteria alone. Therefore, before considering drugs to be avoided and drugs to be used, it is essential to briefly review the course of normal blood pressure during pregnancy, the classification of hypertensive disorders which complicate pregnancy and the pathophysiology of these disorders in pregnancy, focusing on preeclampsia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Friedman EA, Neff RK: Pregnancy hypertension: a systematic evaluation of clinical diagnostic criteria. PSG Publishing Company, Littleton MA, 1977.
Page EW, Christianson R: The impact of mean arterial pressure in the middle trimester upon the outcome of pregnancy. Am J Obstet Gynecol, 125: 740–746, 1976.
Fletcher AE, Bulpitt CJ: A review of clinical trials in pregnancy hypertension. In: “Hypertension in pregnancy” (Ed PC Rubin), Elsevier, New York, 1988, pp 186–201.
Rubin PC, Butters L, Clark DM, Reynolds B, Sumner DJ, Steedman D, Low RA, Reid JL: Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet, I: 431–434, 1983.
Whichman K, Ryden G, Karlberg G: A placebo controlled trial of metoprolol in the treatment of hypertension during pregnancy. Scand J Clin Lab Invest, 44(Suppl 169): 90–95, 1984.
Leather HM, Humphreys DM, Baker P, Chadd MA: A controlled trial of hypertensive agents in hypertension of pregnancy. Lancet, II: 488–490, 1968.
Walker JJ, Crooks A, Erwin L, Calder AA: Labetalol in pregnancy-induced hypertension: fetal and maternal effects. In: “The investigation labetalol in the management of hypertension in pregnancy” (Eds A Riley, EM Symonds), Excerpta Medica, Amsterdam, 1982, pp 148–160.
Redman CWG, Beilin LJ, Bonnar J: Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br J Obstet Gynecol, 84: 419–426, 1977.
Venuto RC, Cox JW, Stein JH, Ferris TF: The effect of changes in perfusion pressure on uteroplacental blood flow in the pregnant rabbit J Clin Invest, 57: 938–941, 1976.
Ladner C, Brinkman CR III, Weston P, Assali NS: Dynamics of uterine circulation in pregnant and nonpregnant sheep. Am J Physiol, 218: 257–263, 1970.
De Swiet M, Hoffbrand BI: Effect of bethanidine on placental blood flow in conscious rabbits. Am J Obstet Gynecol, 111: 374–378, 1971.
Greiss FC Jr: Uterine pressure flow relationships. In: “Uterine and placental blood flow” (Eds AH Moawad, MD Lindheimer), Masson, New York, 1982, pp 67–71.
Ferris TF: Toxaemia and hypertension. In: “Medical complications during pregnancy” (Eds GN Burrow, TF Ferris), 3rd Edition, WB Saunders, Philadelphia, 1988, pp 1–33.
Gallery EDM, Saunders DM, Hunyor SM, Gyory AZ: Randomised comparison of methyldopa and Oxprenolol for treatment of hypertension in pregnancy. Br Med J, I: 1591–1594, 1979.
Sibai BM, Ardella TM, Anderson GD: Pregnancy outcome in 21 patients with mild chronic hypertension. Obstet Gynecol, 61: 571–576, 1983.
Pritchard JA, MacDonald PC, Gant NF: Williiams Obstetrics, 17th edition, Appleton Century Crofts, Norwalk CT, 1985.
Wallenburg HCS: Hemodynamics in hypertensive pregnancy. In: “Hypertension in pregnancy” (Ed PC Rubin), Elsevier, New York, 1988, pp 66–101.
Kuzniar J, Skret A, Piela A, Szmiegel Z, Zaczek T: Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension. Obstet Gynecol, 66: 453–458, 1985.
Belfort M, Uys P, Dommisse J, Davey DA: Hemodynamic changes in gestational proteinuric hypertension: the effects of rapid volume expansion and vasodilator therapy. Br J Obstet Gynecol, 96: 634–641, 1989.
Jouppila P, Kirkinen P, Koivula A, Ylikorkala O: Effects of dihydralazine infusion on the fetoplacental blood flow and maternal prostanoids. Obstet Gynecol, 65: 115–118, 1985.
Nylund L, Lunell NO: Dihydralazine and the uteroplacental blood flow. Am J Obstet Gynecol, 158: 440–441, 1988 (Letter).
Suonio S, Saarikoski S, Tahvanainen K, Paakkonen A, Olkkonen H: Acute effects of dihydralazine mesylate, furosemide, and metoprolol on maternal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol, 155: 122–125, 1895.
Lipshitz J, Ahokas AR, Reynolds SL: The effect of hydralzine on placental perfusion in the spontaneously hypertensive rat. Am J Obstet Gynecol, 156: 356–359, 1987.
Vink GJ, Moodley J, Philpott RH: Effect of dihydralazine on the fetus in the treatment of maternal hypertension. Obstet Gynecol, 55: 519–522, 1980.
Mabie WC, Gonzalez AR, Sibai BM, Amon E: A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol, 70: 328–333, 1987.
Harake B, Gilbert RD, Ashwal S, Power GG: Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep. Am J Obstet Gynecol, 157: 1003–1008, 1987.
Dusay CA, Cook MJ, Veille JC: Cardiorespiratory effects of calcium channel blocker tocolysis in pregnant rhesus monkeys. In: “The physiological development of the fetus and newborn” (Eds CT Jones, PW Nathanielsz), Academic Press, London, 1985, pp 423–428.
Parisi VM, Salinas J, Stockmar EJ: Fetal vascular responses to maternal nicardipine administration in the hypertensive ewe. Am J Obstet Gynecol, 161: 1035–1039, 1989.
Parisi VM, Salinas J, Stockmar EJ: Placental vascular responses to nicardipine in the hypertensive ewe. Am J Obstet Gynecol, 161: 1039–1043, 1989.
Ahokas RA, Sibai BM, Anderson GD: Nifedipine does not adversely affect uteroplacental blood flow in the hypertensive term-pregnant rat. Am J Obstet Gynecol, 159: 1440–1445, 1988.
Pirhonen JP, Erkkola RU, Ekblad U: Uterine and fetal flow velocity waveforms in hypertensive pregnancy: the effect of a single dose of nifedipine. Obstet Gynecol, 76: 37–41, 1990.
Hanretty KP, Whittle MJ, Howie CA, Rubin PC: Effect of nifedipine on doppler flow velocity waveforms in severe pre-eclampsia. Br Med J, 299: 1205–1206, 1989.
Mari G, Kirshon B, Moise KJ, Lee W, Cotton DB: Doppler assessment of the fetal and uteroplacental circulation during nifedipine therapy for preterm labor. Am J Obstet Gynecol, 161: 1514–1518, 1989.
Lindow SW, Davies N, Davey DA, Smith JA: The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy. Br J Obstet Gynecol, 95: 1276–1281, 1988.
Walters BNJ, Redman CWG: Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine. Br J Obstet Gynecol, 91: 330–336, 1984.
Fenakel K, Fenakel G, Appelman Z, Lurie S, Katz Z, Shoham Z: Nifedipine in the treatment of severe pre-eclampsia. Obstet Gynecol, 77: 331–337, 1991.
Walker JJ, Greer I, Calder AA: Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. Postgrad Med J, 52: 390–394, 1983.
Davey DA, Dommisse J, Garden A: Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. In: “The investigation of labetalol in the management of hypertension in pregnancy” (Eds A Riley, EM Symonds), Excerpta Medica, Amsterdam, 1982, pp 51–61.
Ashe RG, Moodley J, Richards AM, Philpott RH: Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. S Afir Med J, 71: 354–356, 1987.
Lunell NO, Nylund L, Lewander R, Sarby B: Acute effect of an antihypertensive drug, labetalol, on uteroplacental blood flow. Br J Obstet Gynecol, 89: 640–644, 1982.
Sibai BM, Spinnato JA, Watson DL, Lewis JA, Anderson GD: Effect of magnesium sulphate on electroencephalographic findings in preeclampsia-eclampsia. Obstet Gynecol, 64: 261–266, 1984.
Thurnau GR, Kemp DB, Jarvis A: Cerebrospinal fluid levels of magnesium in patients with preeclampsia after treatment with intravenous magnesium sulphate: a preliminary report. Am J Obstet Gynecol, 157: 1435–1438, 1987.
Rothman SM, Olney JW: Excitotoxicity and the NMDA receptor. Trends Neurol Sci, 10: 299–302, 1987.
Rothman SM: Synaptic activity mediates death of hypoxic neurones. Science, 220: 536–537, 1984.
Finkbeiner S, Stevens CF: Application of quantitative measurements for assessing neurotoxicity. Proc Natl Acad Sci USA, 85: 4071–4074, 1988.
Pritchard JA, Cunningham FG, Pritchard SA: The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 cases. Am J Obstet Gynecol, 148: 951–963, 1984.
Sibai BM: Magnesium sulphate is the ideal anticonvulsant in preeclampsia-eclampsia. Am J Obstet Gynecol, 162: 1141–1145, 1990.
Sibai BM, Lipshitz J, Anderson GD, Dilts PV Jr: Reassessment of intravenous MgSO4 therapy in preeclampsia-eclampsia. Obstet Gynecol, 51: 199–202, 1981.
Lamm CI, Norton KI, Murphy RJC, Wilkins IA, Rabinowitz JG: Congenital rickets associated with magnesium sulfate infusion for tocolysis. J Pediatr, 113: 1078–1082, 1988.
Crowther C: Magnesium sulphate versus diazepam in the management of eclampsia: a randomised controlled trial. Br J Obstet Gynecol, 97: 110–117, 1990.
Slater RM, Wilcox FL, Smith WD, Donnai P, Patrick J, Richardson T, Mawer GE, D’Souza SW, Anderton JM: Phenytoin infusion in severe pre-eclampsia. Lancet, I: 1417–1420, 1987.
Moosa SM, El Zayat SG: Phenytoin infusion in severe pre-eclampsia. Lancet, II: 1147–1148, 1987.
Tuffnell D, O’Donovan P, Lilford RJ, Prys-Davies A, Thornton JG: Phenytoin in pre-eclampsia. Lancet, I: 273–274, 1989.
Dommisse J: Phenytoin sodium and magnesium sulphate in the management of eclampsia. Br J Obstet Gynecol, 97: 104–109, 1990.
Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD: A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol, 162: 960–967, 1990.
Fidler J, Smith V, Fayers P, De Swiet M: Randomised controlled comparative study of methyldopa and Oxprenolol in treatment of hypertension in pregnancy. Br Med J, 286: 1927–1930, 1983.
Moar VA, Jefferies MA, Mutch LMM: Neonatal head circumference and the treatment of maternal hypertension. Br J Obstet Gynecol, 85: 933–937, 1978.
Ounsted MK, Moar VA, Good FJ, Redman CWG: Hypertension during pregnancy with and without specific treatment; the development of the children at the age of four years. Br J Obstet Gynecol, 87: 19–24, 1980.
Cockburn J, Moar VA, Ounsted M, Redman CWG: Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet, I: 647–649, 1982.
Hogstedt S, Lindeberg S, Axelsson O et al: A prospective controlled trial of metoprolol-hydralazine treatment in hypertension during pregnancy. Acta Obstet Gynecol Scand, 64: 505–510, 1985.
Bott-Kanner G, Schweitzr A, Reisner SH, Joel-Cohen SJ, Rosenfeld JB. Propranolol and hydralazine in the management of essential hypertension in pregnancy. Br J Obstet Gynecol, 87: 110–114, 1980.
Rosenfeld J, Bott-Kanner G, Boner G et al: Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol. Eur J Obstet Gynecol Reprod Biol, 22:197–204, 1986.
Widerlov E, Karlman I, Storsater J: Hydralazine-induced neonatal thrombocytopenia N Engl J Med, 303: 1235–1237, 1980.
Lieberman BA, Stirrat GM, Donen SL, Beard RW, Pinker GD, Belsey E: The possible adverse effect of propranolol on the fetus in pregnancies complicated by severe hypertension. Br J Obstet Gynecol, 85: 678–683, 1978.
Jouppila P, Kirkinen P, Koivula A, Ylikorkala O: Labetalol does not alter the placental and fetal blood flow or maternal prostanoids in pre-eclampsia. Br J Obstet Gynecol, 93: 543–547, 1986.
Haraldsson A, Geven W: Serious adverse effects of maternal labetalol in a premature infant. Acta Pediatr Scand, 78: 956–958, 1989.
Woods DL, Morrell DF: Atenolol: side effects in a newborn infant. Br Med J, 285: 691–692, 1982.
Macpherson M, Broughton Pipkin F, Rutter N: The effect of maternal labetalol on the newborn infant. Br J Obstet Gynecol, 93: 539–542, 1986.
Dumez Y, Tchobroutsky, Hornych H, Amiel-Tsion C: Neonatal effects of maternal administration of acebutolol. Br Med J, 283: 1077–1079, 1981.
Sibai BM, Gonzalez AR, Mabie WC, Moretti M: A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol, 70: 323–327, 1987.
Pickles CJ, Symonds EM, Broughton Pipkin F: The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynecol, 96: 38–43, 1989.
Plouin PF, Breart G, Llado J, Dalle M, Keller ME, Goujon H, Berchel C: A randomised comparison or early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension. Br J Obstet Gynecol, 97: 134–141, 1990.
Reynolds B, Butters L, Evans J, Adams T, Rubin PC: First year of life after the use of atenolol in pregnancy associated hypertension. Arch Dis Child, 59: 1061–1063, 1984.
Constantine G, Beevers DG, Reynolds AL, Luesley DM: Nifedipine as a second line antihypertensive drug in pregnancy. Br J Obstet Gynecol, 94: 1136–1142, 1987.
Schubiger G, Flury G, Nussberger J: Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med, 108: 215–216, 1988.
Broughton Pipkin F, Symonds EM, Turner SR: The effect of Captopril (SQ14225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit. J Physiol, 323: 415–422, 1982.
Ferris TF, Weir EK: Effect of Captopril on uterine blood flow and prostaglandin synthesis in the pregnant rabbit. J Clin Invest, 71: 809–815, 1983.
Lubbe WF, Hodge JV: Combined alpha and beta-adrenceptor antagonism with prazosin and Oxprenolol in control of severe hypertension in pregnancy. NZ Med J, 94: 169–172, 1981.
Dommisse J, Davey DA, Roos PJ: Prazosin and Oxprenolol therapy in pregnancy hypertension. S Afr Med J, 64: 231–233, 1983.
Rubin PC, Butters L, Low RA, Reid JL. Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension. Br J Clin Pharmacol, 16: 543–547, 1983.
Devoe LD, O’Dell BE, Castillo RA, Hadi HA, Saerle N: Metastatic phaeochromocytoma in pregnancy and fetal biophysical assessment after maternal administration of alpha-adrenergic, beta-adrenergic and dopamine antagonists. Obstet Gynecol, 68 (Suppl): 15S–18S, 1986.
Venuto R, Burstein P, Schneider R: Phaeochromocytoma: antepartum diagnosis and management with tumor resection in the Puerperium. Am J Obstet Gynecol, 150: 431–432, 1984.
Belizan JM, Villar J, Repke J: The relationship between calcium intake and pregnancy-induced hypertension: up-to-date evidence. Am J Obstet Gynecol, 158: 898–902, 1988.
Taufield PA, Ales KL, Resnick LM, Druzin ML, Gertner JM, Laragh JH: Hypocalciuria in preeclampsia. N Engl J Med, 316: 715–718, 1987.
Kawasaki N, Matsui K Ito M et al: Effect of calcium supplementation on the vascular sensitivity to angiotensin II in pregnant women. Am J Obstet Gynecol, 153: 576–582, 1985.
Montanaro D, Bascutti G, Antonucci F, et al: Prevention of pregnancy-induced hypertension (PIH) and preeclampsia (PE) by oral calcium supplementation. 10th Int Congress Nephrol: 291, 1987, (Abstract).
Bamford DS, Jogee M, Williams KI: Prostacyclin formation by pregnant human myometrium. Br J Obstet Gynecol, 87: 215, 1980.
Mitchell MD, Bibby JB, Hicks BR, Tumbull AC: Possible role for prostacyclin in human parturition. Prostaglandins, 16: 931, 1978.
Rakoczi I, Tihanyi K, Falkay G, Rosza I, Demaler J, Gati I: Prostacyclin production in trophoblast. In: “Prostacyclin and pregnancy” (Eds PJ Lewis, S Moncada, J O’Grady), Raven Press, New York, 1983, pp 15–23.
Spitz B, Deckmyn H, van Assche FA, Vermylen J: Prostacyclin production in whole blood throughout normal pregnancy. In: “Clinical and experimental hypertension. Part B. Hypertension in pregnancy” (Eds FP Zuspan, EM Symonds), Marcel Dekker, New York, 1983, pp 191–202.
Mitchell MD: Prostacyclin during human pregnancy and parturition. In: “Clinical pharmacology of prostacyclin” (Eds PJ Lewis, J O’Grady), Raven Press, New York, 1981, pp 121–129.
Ylikorkola O, Viinikka L: Maternal plasma levels of 6-keto-prostaglandin F1-alpha during pregnancy and Puerperium. Prostaglandins Leukotrienes Med, 7: 95, 1981.
Koullapis EN, Nicolaides KH, Collins WP, Rodeck CH, Campbell S: Plasma prostanoids in pregnacy-induced hypertension. Br J Obstet Gynecol, 89: 617, 1982.
Lewis PJ, Boylan P, Friedman LA, Hensby CN, Downing I: Prostacyclin in pregnancy. Br Med J, 280: 1581, 1980.
Fitzgerald DJ, Entman SS, Mulloy K, Fitzgerald GA: Decreased prostacyclin biosynthesis preceeding the clinical manifestation of pregnancy-induced hypertension. Circ, 5: 956–963, 1987.
Fitzgerald DJ, Mayo G, Catella F, Entman SS, Fitzgerald GA: Increased thromboxane biosynthesis in normal pregnancy is mainly derived from platelets. Am J Obstet Gynecol, 157: 325–330, 1987.
Fitzgerald DJ, Rocki W, Murray R, Mayo G, Fitzgerald GA: Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet, 335: 751–754, 1990.
Sibai BM, Mirro R, Chesney CM, Leffler C: Low-dose aspirin in pregnancy. Obstet Gynecol, 74: 551–556, 1989.
Nelson DM, Walsh SW: Aspirin differentially affects thromboxane and prostacyclin production by trophoblast and villous core compartments of human placental villi. Am J Obstet Gynecol, 161: 1593–1598, 1989.
Schiff E, Peleg E, Goldenberg M, Rosenthal T, Ruppin E, Tamarkin M, Barkai G, Ben-Baruch G, Yahal I, Blankstein J, Goldman B, Mashiach S: The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med, 321: 351–356, 1989.
Benigni A, Gregorina G, Frasca T, Chiabrando C, Ballerini S, Valcamonico A, Orisio s, Piccinelli A, Pinciroli V, Fanelli R, Gastaldi A, Remuzzi G: Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med, 321: 357–362, 1989.
Stuart MJ, Gross SJ, Elrad H, Graeber JE: Effects of acetylsalicylic-acid on maternal and neonatal hemostasis. N Engl J Med, 307: 909–912, 1982.
Beaufils M, Uzan S, Donsimoni R, Colau JC: Prevention of pre-eclampsia by early antiplatelet therapy. Lancet, I: 840–842, 1985.
Wallenburg HCS, Dekker GA, Makovitz JW, Rotmans P: Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive Primigravidae. Lancet, I: 1–3, 1986.
McParland P, Pearce JM, Chamberlain GVP: Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet, 335: 1552–1555, 1990.
Uzan S, Beaufils M, Breart G, Bazin B, Capitant C, Paris J: Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet, 337: 1427–1431, 1991.
Zierler S, Rothman KJ: Congenital heart disese in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med, 313: 347–352, 1985.
Werler MM, Mitchell AA, Shapiro S: The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med, 321: 1639–1642, 1989.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag London Limited
About this chapter
Cite this chapter
Sturgiss, S.N., Lindheimer, M.D., Davison, J.M. (1991). Treatment of Hypertension During Pregnancy: Drugs to be Avoided and Drugs to be Used. In: Andreucci, V.E., Fine, L.G. (eds) International Yearbook of Nephrology 1992. Springer, London. https://doi.org/10.1007/978-1-4471-1892-3_7
Download citation
DOI: https://doi.org/10.1007/978-1-4471-1892-3_7
Publisher Name: Springer, London
Print ISBN: 978-1-4471-1894-7
Online ISBN: 978-1-4471-1892-3
eBook Packages: Springer Book Archive